Loading
SEED Therapeutics designs molecular glues, tablet drugs that make the cell's own disposal system destroy a chosen protein. Its first cancer drug, ST-01156, removes a protein called RBM39 and is in an early trial for advanced solid tumours, including Ewing sarcoma and liver cancer.
SEED Therapeutics, Inc., at 411 Swedeland Road, King of Prussia, Pennsylvania, develops rationally designed molecular glue degraders with its RITE3 platform, which it says gives access to more than 600 human E3 ubiquitin ligases rather than the two most used in the field. It was co-founded by Nobel laureate Avram Hershko, chief executive and chair Lan Huang (co-founder and chair of BeyondSpring), Ning Zheng of the University of Washington and Michele Pagano of New York University, and lists partnerships with Lilly and Eisai. Its lead programme ST-01156 is an oral, brain-penetrant RBM39 molecular glue degrader in a first-in-human phase 1/1b study in advanced solid malignancies, with a focus on RBM39-dependent cancers such as Ewing sarcoma, hepatocellular carcinoma and biliary tract cancer; the company presented the trial at ASCO in June 2026 and preclinical neuroblastoma data at AACR 2026. The pipeline also includes tau and mutant huntingtin degraders for neurodegeneration and an immunology programme. Its first registered cancer trial, NCT07197554, was posted on ClinicalTrials.gov in September 2025.
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares PROTACs & molecular glues (targeted protein degradation), Neuroblastoma (paediatric), Hepatocellular carcinoma.
Shares Neuroblastoma (paediatric), Hepatocellular carcinoma.
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Shares Neuroblastoma (paediatric), Hepatocellular carcinoma.
Shares Neuroblastoma (paediatric), Hepatocellular carcinoma.
Shares Biliary tract cancer (all types), Hepatocellular carcinoma.
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/